Order results by:
| Issue | Title | |
| Vol 11, No 6 (2015) | Clinical and economic analysis of the use of apixaban for the treatment of venous thromboembolic events | Abstract similar documents |
| O. V. Shatalova | ||
| "... (bleeding) in the conventional therapy group was 4.8 times higher than the costs in apixaban group ..." | ||
| Vol 11, No 5 (2015) | Cost-effectiveness of new oral anticoagulants in the treatment and secondary prevention of venous thromboembolism | Abstract similar documents |
| A. V. Rudakova | ||
| "... with comparable efficacy in treatment and secondary prevention of VTE. Apixaban therapy costs were lower than ..." | ||
| Vol 11, No 3 (2015) | PHARMACOECONOMIC ASPECTS OF THE PREVENTION OF VENOUS THROMBOEMBOLIC EVENTS AFTER LARGE JOINTS REPLACEMENT | Abstract similar documents |
| A. V. Rudakova | ||
| "... . To assess the cost-effectiveness of different options for the prevention of VTE events in hip and knee ..." | ||
| Vol 20, No 4 (2024) | Should a physician use the Beers criteria when prescribing direct oral anticoagulants to elderly patients? | Abstract similar documents |
| N. M. Vorobyeva, I. P. Malaya, V. D. Zakiev, O. N. Tkacheva | ||
| "... ) and venous thromboembolic complications (VTE) should be avoided in favor of safer alternative anticoagulants ..." | ||
| Vol 11, No 1 (2015) | PHARMACOECONOMIC ASPECTS OF APIXABAN FOR PREVENTION OF THROMBOEMBOLIC EVENTS IN PATIENTS WITH ATRIAL FIBRILLATION | Abstract similar documents |
| A. V. Rudakova | ||
| "... apixaban is expected to be cost-effective alternative from the Russian Federation national healthcare ..." | ||
| Vol 16, No 5 (2020) | Pharmacokinetics and Pharmacogenetics of Apixaban | Abstract similar documents |
| A. V. Savinova, M. M. Petrova, N. A. Shnayder, E. N. Bochanova, R. F. Nasyrova | ||
| "... Apixaban is oral anticoagulant, it is widely used in prevention of stroke in non-valvular atrial ..." | ||
| Vol 13, No 1 (2017) | CLINICAL AND ECONOMICAL COMPARISON OF RIVAROXABAN AND APIXABAN USE IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION | Abstract similar documents |
| S. V. Nedogoda, I. N. Barykina, A. S. Salasiuk, V. O. Smirnova | ||
| "... with "decision tree" modeling is performed. The costs of regimens using rivaroxaban and apixaban were calculated ..." | ||
| Vol 14, No 2 (2018) | NEW DIRECT ORAL ANTICOAGULANTS FOR TREATMENT OF PATIENTS WITH ATRIAL FIBRILLATION IN REAL-WORLD SETTING | Abstract similar documents |
| Zh. D. Kobalava, S. V. Villevalde, A. A. Shavarov | ||
| "... . In comparison of different DOACs against each other apixaban demonstrated lower bleeding risk while patients ..." | ||
| Vol 16, No 2 (2020) | The Current Status of Direct Oral Anticoagulants in Cancer-Related Venous Thromboembolism Treatment | Abstract similar documents |
| К. V. Lobastov, I. V. Schastlivtsev | ||
| "... patients have been published: SELECT-D (rivaroxaban), HOKUSAI-VTE Cancer (edoxaban), ADAM VTE (apixaban ..." | ||
| Vol 10, No 3 (2014) | COST-EFFECTIVENESS OF APIXABAN AS COMPARED WITH WARFARIN AND ACETYLSALICYLIC ACID IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION IN THE RUSSIAN FEDERATION | Abstract similar documents |
| A. V. Rudakova, V. A. Parfenov | ||
| "... in patients with NVAF in the Russian Federation. Aim. To evaluate the cost-effectiveness ratio of apixaban ..." | ||
| Vol 11, No 3 (2015) | ANALYSIS OF THE INFLUENCE OF THROMBOEMBOLIC COMPLICATIONS PREVENTION WITH ORAL ANTICOAGULANTS ON BUDGET IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION | Abstract similar documents |
| A. V. Rudakova | ||
| "... can be explained by both the lower cost of apixaban in comparison with reference drugs ..." | ||
| Vol 12, No 3 (2016) | THE PHARMACOKINETICS OF APIXABAN IN PATIENTS WITH CARDIOEMBOLIC STROKE IN ACUTE PHASE | Abstract PDF (Eng) similar documents |
| A. V. Kryukov, D. A. Sychev, D. A. Andreev, A. V. Ryabova, N. P. Denisenko, M. A. Loskutnikov, O. I. Vinogradov, M. A. Domashenko | ||
| "... Aim. To study pharmacokinetics of apixaban in patients with atrial fibrillation and cardioembolic ..." | ||
| Vol 11, No 5 (2015) | Practical aspects of apixaban use in clinical practice: continuing the theme | Abstract similar documents |
| S. N. Bel'diev | ||
| "... Currently there are no generally accepted guidelines for the use of apixaban together with CYP3A4 ..." | ||
| Vol 15, No 2 (2019) | Studies of Anticoagulant Therapy in Frail Elderly Patients: Problems of Terminology and Methodology | Abstract similar documents |
| S. N. Bel'diev, I. V. Medvedeva, D. Yu. Platonov, G. Yu. Trufanova | ||
| Vol 15, No 2 (2019) | Studies of Anticoagulant Therapy in Frail Elderly Patients: Problems of Terminology and Methodology | Abstract similar documents |
| Sergey N. Bel'diev, Irina V. Medvedeva, Dmitry Yu. Platonov, Galina Yu. Trufanova | ||
| Vol 10, No 3 (2014) | EUROPEAN MEDICINES AGENCY APPROVED APIXABAN USE IN CARDIOVERSION | Abstract similar documents |
| "... European Medicines Agency approved apixaban use in cardioversion. ..." | ||
| Vol 11, No 2 (2015) | PRACTICAL ASPECTS OF APIXABAN USE IN CLINICAL PRACTICE: VIEW POINT OF CLINICAL PHARMACOLOGIST | Abstract similar documents |
| D. A. Sychev, I. I. Sinitsina, G. Yu. Zakharova, M. I. Savel'eva, A. V. Ryabova, A. V. Kryukov, A. Yu. Yurovskii | ||
| "... Apixaban is a "new" oral anticoagulant, direct Xa factor inhibitor with a good evidence base ..." | ||
| Vol 17, No 6 (2021) | Anticoagulants after Discharge in Patients with COVID-19: What we Know at the End of 2021 | Abstract similar documents |
| I. S. Yavelov | ||
| "... VTE risk score with the addition of elevated in-hospital D-dimer level. And the most well-studied ..." | ||
| Vol 18, No 5 (2022) | Thrombocytopenia Induced by Direct Oral Anticoagulants: a Clinical Case and Literature Review | Abstract similar documents |
| B. A. Tatarsky, N. V. Kazennova | ||
| "... thrombin blockers (dabigatran) or factor IIa blockers (apixaban, rivaroxaban, edoxaban). According ..." | ||
| Vol 13, No 5 (2017) | DRUG INTERACTIONS OF NEW ORAL ANTICOAGULANTS: INSIDE AND OUTSIDE TABLE CELLS | Abstract similar documents |
| S. N. Bel'diev, I. V. Medvedeva, D. Yu. Platonov | ||
| Vol 16, No 2 (2020) | The Risk of Myocardial Infarction in Patients with Atrial Fibrillation Taking a Direct Thrombin Inhibitor: Myths and Reality | Abstract similar documents |
| B. A. Tatarsky, N. V. Kazennova, D. A. Napalkov | ||
| Vol 13, No 5 (2017) | Drug interactions of non-vitamin K antagonist oral anticoagulants: inside and outside table cells | Abstract similar documents |
| Sergey Nikolaevich Bel'diev, Irina Vladimirovna Medvedeva, Dmitry Jur'evich Platonov | ||
| Vol 18, No 3 (2022) | Clinically Significant Drug Interactions for Direct Oral Anticoagulants: State of the Art | Abstract similar documents |
| S. R. Gilyarevsky | ||
| "... interactions of apixaban, rivaroxaban and dabigatran with the drugs most frequently used in patients ..." | ||
| Vol 18, No 6 (2022) | Effect of ABCB1 Gene Carriage and Drug-Drug Interactions on Apixaban and Rivaroxaban Pharmacokinetics and Clinical Outcomes in Patients with Atrial Fibrillation and Deep Vein Thrombosis | Abstract similar documents |
| L. V. Fedina, I. N. Sychev, T. D. Rastvorova, E. V. Strigunkova, A. A. Kachanova, Z. A. Sozaeva, P. O. Bochkov, A. V. Vardanyan, K. B. Mirzayev, D. A. Sychev | ||
| "... Aim. To investigate the effect of ABCB1 gene carriage and interdrug interactions on apixaban ..." | ||
| Vol 12, No 4 (2016) | Clinical significance of new oral anticoagulants in the prevention of thromboembolic complications in patients with atrial fibrillation: not all dreams come true | Abstract similar documents |
| Yu. A. Bunin, S. V. Miklishanskaya | ||
| Vol 13, No 1 (2017) | DATA OF CLINICAL PRACTICE AS A TOOL FOR CHOICE OF DIRECT ORAL ANTICOAGULANT | Abstract similar documents |
| D. А. Napalkov, A. A. Sokolova, V. V. Fomin | ||
| "... anticoagulants, apixaban is associated with the best adherence to treatment and lowest bleeding incidence ..." | ||
| Vol 13, No 3 (2017) | PHARMACOGENETIC ASPECTS OF NEW ORAL ANTICOAGULANTS APPLICATION | Abstract similar documents |
| A. V. Kryukov, D. A. Sychev, O. V. Tereshchenko | ||
| "... 1045642 polymorphisms. ABCB1 gene rs4148738 polymorphism was associated with higher apixaban peak ..." | ||
| Vol 7, No 5 (2011) | ANTITHROMBOTIC THERAPY IN ATRIAL FIBRILLATION: RECENT APPROACHES AND NEAR PERSPECTIVES | Abstract similar documents |
| Ya. P. Dovgalevskiy, L. E. Kuvshinova, I. V. Graifer, N. V. Furman, P. Ya. Dovgalevskiy | ||
| Vol 9, No 3 (2013) | ANTICOAGULANT THERAPY IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION: DRUG CHOICE AND DOSAGE ADJUSTMENT | Abstract similar documents |
| E. L. Dolgova, I. M. Sokolov, Yu. G. Shvarts | ||
| Vol 9, No 4 (2013) | COMPARATIVE EFFICACY AND SAFETY OF NEW ORAL ANTICOAGULANTS | Abstract similar documents |
| V. A. Sulimov, D. A. Napalkov, A. A. Sokolova | ||
| "... Indirect comparisons of new oral anticoagulants are performed with focus on their safety. Apixaban ..." | ||
| Vol 10, No 4 (2014) | NEW ORAL ANTICOAGULANTS: FOCUS ON THE SAFETY | Abstract similar documents |
| D. A. Napalkov, A. A. Sokolova | ||
| "... dabigatran, rivaroxaban and apixaban) is presented from the standpoint of safety. The safety profile ..." | ||
| Vol 16, No 1 (2020) | Control Of Anticoagulation Therapy in Atrial Fibrillation (COAT-AF Study) in Real Clinical Practice | Abstract similar documents |
| A. A. Zarudsky, A. A. Gavrilova, Т. S. Filinichenko | ||
| Vol 17, No 1 (2021) | Direct Oral Anticoagulants in Patients with Atrial Fibrillation and Renal Dysfunction | Abstract similar documents |
| Z. D. Kobalava, A. A. Shavarov, M. V. Vatsik-Gorodetskaya | ||
| Vol 17, No 2 (2021) | Anticoagulant Therapy in Patients with Non-valvular Atrial Fibrillation in Real Clinical Practice: in Appropriate Dose Reductions | Abstract similar documents |
| V. A. Ionin, O. I. Bliznuk, E. I. Baranova, E. V. Shlyakhto | ||
| "... : rivaroxaban - 180/384 (46,9%) patients, dabigatran etexilate - 110/384 (28,6%) patients, apixaban - 94/384 (24 ..." | ||
| Vol 15, No 5 (2019) | Rivaroxaban-Associated Hepatotoxicity: a Clinical Case and Literature Review | Abstract similar documents |
| B. A. Tatarsky, N. V. Kazennova, D. A. Napalkov | ||
| Vol 14, No 3 (2018) | APPROACHES TO THE CHOICE OF ANTICOAGULANT THERAPY IN THE TREATMENT OF PATIENTS WITH COMBINATION OF ATRIAL FIBRILLATION WITH CORONARY HEART DISEASE OR PERIPHERAL ATHEROSCLEROSIS: POTENTIAL OF APIXABAN | Abstract similar documents |
| O. D. Ostroumova, A. I. Kochetkov, I. Yu. Orlova, E. A. Smolyarchuk, J. S. Pavlova | ||
| "... of efficacy and safety of apixaban in patients with AF, depending on the presence of CHD, PAD, concomitant use ..." | ||
| Vol 12, No 2 (2016) | ATRIAL FIBRILLATION AND ISCHEMIC HEART DISEASE: HOW TO COMBINE ANTIPLATELET AND ANTICOAGULANT THERAPY, DEPENDING ON THE CLINICAL SITUATION? | Abstract similar documents |
| D. A. Napalkov, A. A. Sokolova, A. V. Rodionov | ||
| "... and safety of apixaban with these of warfarin in patients with atrial fibrillation and a history of ischemic ..." | ||
| Vol 13, No 6 (2017) | PREDICTORS OF THE RISK OF HEMORRHAGIC EVENTS IN PATIENTS WITH ATRIAL FIBRILLATION RECEIVING LONGTERM THERAPY WITH DIRECT ORAL ANTICOAGULANTS | Abstract similar documents |
| A. А. Sokolova, A. V. Zhilenko, I. L. Tsarev,, D. A. Napalkov, V. V. Fomin | ||
| "... – rivaroxaban and apixaban) were included into the cohort study in parallel groups. In addition to evaluate ..." | ||
| Vol 15, No 6 (2019) | Safety of Non-Vitamin K Oral Anticoagulants in Elderly Patients with Atrial Fibrillation | Abstract similar documents |
| M. A. Gabitova, P. M. Krupenin, A. A. Sokolova, D. A. Napalkov, V. V. Fomin | ||
| "... of age with confirmed AF, receiving dabigatran in a reduced dosage, apixaban or rivaroxaban in full ..." | ||
| Vol 16, No 1 (2020) | The Efficacy, Safety and Adherence to Treatment when New Anticoagulants Taking in Over 75 Years Old Patients with Atrial Fibrillation | Abstract similar documents |
| A. N. Turov, S. V. Panfilov, О. V. Tschiglinzeva | ||
| "... , rivaroxaban – in 41.3% (n=178), apixaban – in 20.2% (n=87) of patients. Results. The incidence of new cases ..." | ||
| Vol 16, No 2 (2020) | Off-Label Medicines Use: Complex Problem of Modern Clinical Practice | Abstract similar documents |
| S. R. Gilyarevskiy | ||
| Vol 14, No 3 (2018) | THROMBOSIS OF LEFT ATRIAL APPENDAGE DURING THERAPY WITH DIRECT ORAL ANTICOAGULANT. CLINICAL CASE | Abstract similar documents |
| I. S. Daaboul, S. Yu. Koroleva, A. A. Kudrjavtseva, A. A. Sokolova, D. A. Napalkov, V. V. Fomin | ||
| "... long-term anticoagulant therapy with apixaban in a full dose (5 mg b.i.d.), and the patient ..." | ||
| Vol 14, No 4 (2018) | Hepatotoxicity of New Oral Anticoagulants | Abstract similar documents |
| A. R. Kasimova, A. V. Philippova (Guryanova), A. S. Kolbin | ||
| Vol 16, No 6 (2020) | An Elderly Comorbid Patient with Atrial Fibrillation: What is Important to Know and What Should be Considered When Prescribing Anticoagulants? | Abstract similar documents |
| T. V. Pavlova | ||
| Vol 15, No 4 (2019) | Optimization of Pharmacotherapy with Direct Oral Anticoagulants: the Need to Choose the Right Dosage Regimen | Abstract similar documents |
| A. I. Kochetkov, O. D. Ostroumova | ||
| "... profile and multimorbidity. In these terms, apixaban stands high among the DOAC class, and its high ..." | ||
| Vol 19, No 3 (2023) | Current insights into the possible role of laboratory monitoring of effectiveness and safety of direct oral anticoagulants | Abstract similar documents |
| S. R. Gilyarevsky, N. K. Vereina, M. V. Golshmid | ||
| Vol 20, No 1 (2024) | Effect of CYP3A4/5, ABCB1 gene polymorphisms on the residual equilibrium concentration of apixaban and bleeding in patients with non-valvular atrial fibrillation and deep vein thrombosis | Abstract similar documents |
| l. V. Fedina, i. N. Sychev, K. V. Mirzaev, A. V. Vardanyan, S. V. Glagolev, A. A. Kachanova, P. O. Bochkov, R. V. Shevchenko, S. N. Tuchkova, I. V. Sychev, S. P. Abdullaev, D A. Sychev | ||
| "... ) and rs4148738 (c.2692-2236C>T) genes on the plasma concentration of apixaban, on changes in prothrombin ..." | ||
| Vol 12, No 5 (2016) | Features of Modern Anticoagulant Therapy in Patients with Nonvalvular Atrial Fibrillation and Chronic Kidney Disease | Abstract similar documents |
| I. S. Daabul, A. A. Sokolova, D. A. Napalkov | ||
| Vol 16, No 3 (2020) | Clinical and Pathophysiological Aspects of the Effect of Anticoagulants on Bone Tissue | Abstract similar documents |
| O. D. Ostroumova, I. V. Goloborodova | ||
| Vol 18, No 6 (2022) | Left Ventricular Thrombosis: Current Perspective and Use of Direct Oral Anticoagulants | Abstract similar documents |
| A. D. Aga, A. A. Sokolova, D. A. Napalkov | ||
| Vol 15, No 4 (2019) | According to the AUGUSTUS Trial Apixaban (Eliquis ® ) was Found to Be Safer than Vitamin K Antagonists in Patients with Non-Valvular Atrial Fibrillation with Acute Coronary Syndrome and/or Percutaneous Coronary Intervention | Abstract similar documents |
| Company Pfizer | ||
| Vol 12, No 3 (2016) | THE ADVANCED TACTICS OF THE MANAGEMENT OF PATIENTS WITH VENOUS THROMBOEMBOLISM: THE ROLE OF RIVAROXABAN AT VARIOUS STAGES OF TREATMENT | Abstract PDF (Eng) similar documents |
| S. R. Gilyarevskiy | ||
| "... Venous thromboembolism (VTE) is one of the most common cardiovascular disease, and can lead ..." | ||
| Vol 4, No 3 (2008) | THE RUSSIAN DATA OF INTERNATIONAL ENDORSE REGISTER (EPIDEMIOLOGIC INTERNATIONAL DAY FOR THE EVALUATION OF PATIENTS AT RISK OF VENOUS THROMBOSIS IN ACUTE HOSPITAL CARE SETTING) | Abstract similar documents |
| V. A. Sulimov, S. M. Belentsov, N. I. Golovina, N. P. Dubrovnaja, K. P. Zhidkov, K. V. Yeliseyeva, P. O. Kazanchan, A. V. Redkin, G. V. Rodoman, I. L. Fridman, V. N. Shershnev | ||
| "... Aim. To estimate a risk factor frequency of venous thromboembolism (VTE) in patients urgently ..." | ||
| Vol 10, No 6 (2014) | THE PROBLEM OF THE USE OF NEW ORAL ANTICOAGULANTS IN CANCER PATIENTS RECEIVING CHEMOTHERAPY | Abstract similar documents |
| A. A. Rumyantsev, I. A. Pokataev, T. V. Kozlov, N. A. Rumyantsev | ||
| "... Despite large number of known risk factors of venous thromboembolism (VTE) in cancer patients ..." | ||
| Vol 17, No 3 (2021) | Treatment and Secondary Prevention of Venous Thromboembolism in Real Clinical Practice Based on Health Care Professional Survey | Abstract similar documents |
| K. V. Lobastov, A. R. Navasardyan, I. V. Schastlivtsev | ||
| "... Aim. To assess the duration of the anticoagulant treatment of venous thromboembolism (VTE ..." | ||
| Vol 9, No 2 (2013) | ERA OF NEW ANTICOAGULANTS IN THE TREATMENT OF NON-VALVULAR ATRIAL FIBRILLATION: PROSPECTS AND CHALLENGES | Abstract similar documents |
| Z. M. Safiullina, S. V. Shalaev | ||
| "... inhibitors of coagulation factor Xa (rivaroxaban, apixaban), in the treatment of nonvalvular atrial ..." | ||
| Vol 16, No 6 (2020) | The Oral Anticoagulants Administration in Elderly Patients with Geriatric Syndromes: What's New? | Abstract similar documents |
| N. M. Vorobyeva, O. N. Tkacheva | ||
| "... , rivaroxaban, apixaban, and edoxaban) over the vitamin K antagonist warfarin in elderly patients with geriatric ..." | ||
| Vol 18, No 3 (2022) | Risk of Venous Thromboembolic Complications in Patients with Atrial Fibrillation: a Systematic Review and Meta-analysis | Abstract PDF (Eng) similar documents |
| A. A. Sokolova, A. A. Kudriavtseva, N. V. Kostokova, M. P. Zaikina, Z. A. Gebekova, D. A. Napalkov, I. A. Zolotukhin | ||
| "... between AF and VTE. Material and methods. Atrial fibrillation (AF) and atrial flutter (AFL) contribute ..." | ||
| Vol 12, No 6 (2016) | Efficacy and safety of the new oral anticoagulants in the treatment of venous thromboembolic complications: meta-analysis | Abstract PDF (Eng) similar documents |
| V. I. Petrov, O. V. Shatalova, V. S. Gorbatenko, O. N. Smuseva, A. S. Maslakov | ||
| "... of venous thromboembolism (VTE). Material and methods. This meta-analysis of randomized controlled trials ..." | ||
| Vol 12, No 1 (2016) | Efficacy and safety of the new oral anticoagulants in the treatment of venous thromboembolic complications: meta-analysis | Abstract similar documents |
| V. I. Petrov, O. V. Shatalova, V. S. Gorbatenko, O. N. Smuseva, A. S. Maslakov | ||
| "... of venous thromboembolism (VTE). Material and methods. This meta-analysis of randomized controlled trials ..." | ||
| Vol 17, No 4 (2021) | Changes in anticoagulant prescription in a general hospital in 2008-2018 | Abstract similar documents |
| E. B. Kleymenova, V. A. Otdelenov, M. D. Nigmatkulova, S. A. Payushchik, A. A. Chernov, O. D. Konova, L. P. Yashina, A. M. Cherkashov, D. A. Sychev | ||
| "... oral anticoagulants (DOAC) prescription in clinical guidelines for venous thromboembolism (VTE) and AF ..." | ||
| Vol 16, No 4 (2020) | The Controversy Continues Again: which Direct Anticoagulant is More Effective and Safe when Administered to Patients with Atrial Fibrillation? | Abstract similar documents |
| S. Yu. Martsevich | ||
| "... is inferior to apixaban in its ability to prevent ischemic stroke and systemic embolism and is more likely ..." | ||
| Vol 12, No 2 (2016) | THE EFFICACY AND SAFETY OF NEW ORAL ANTICOAGULANTS IN PATIENTS WITH ATRIAL FIBRILLATION IN CLINICAL PRACTICE | Abstract similar documents |
| S. V. Moiseev | ||
| "... New oral anticoagulants that inhibit factor Xa (rivaroxaban, apixaban, edoksaban) or thrombin ..." | ||
| Vol 17, No 5 (2021) | Gastrointestinal Bleeding: a Cardiologist's Point of View | Abstract similar documents |
| O. V. Averkov, L. N. Mishchenko | ||
| "... antagonists (warfarin) as well as direct oral anticoagulants (DOAC): dabigatran, rivaroxaban, apixaban ..." | ||
| Vol 21, No 2 (2025) | Anticoagulant therapy in patients with cardioembolic subtype of ischemic stroke and atrial fibrillation | Abstract similar documents |
| E. A. Naryshkina, M. I. Chashkina, E. S. Zadykyan, N. K. Kurbanalieva, E. M. Zakaryan, M. V. Serova, D. A. Andreev, A. G. Komarova, K. E. Eroshkin, A. A. Kulesh, D. A. Sychev | ||
| "... on outpatient ACT were included; rivaroxaban (n=56), apixaban (n=30), dabigatran etexilate (n=11), and warfarin ..." | ||
| Vol 18, No 1 (2022) | Modern Anticoagulant Therapy for Atrial Fibrillation: Patient Adherence in Clinical Practice | Abstract similar documents |
| Yu. P. Skirdenko, N. A. Nikolaev, K. G. Pereverzeva, A. Yu. Timakova, A. S. Galus, S. S. Yakushin | ||
| "... among anticoagulants (36.7%). About a third of respondents were prescribed apixaban by a doctor (30 ..." | ||
| Vol 15, No 5 (2019) | Findings Released from NAXOS Analysis. Pfizer Company Press Release | Abstract similar documents |
| article Editorial | ||
| "... Компания Pfizer представила результаты когортного исследования NAXOS (EvaluatioN of ApiXaban in ..." | ||
| Vol 5, No 5 (2009) | THE COMPARATIVE COST-EFFICACY ANALYSIS OF VARIOUS ANTIHYPERTENSIVE THERAPIES | Abstract similar documents |
| S. V. Malchikova, E. I. Tarlovskaya | ||
| "... Aim. To perform the comparative cost-efficacy analysis of various antihypertensive therapies ..." | ||
| Vol 7, No 2 (2011) | COST-EFFECTIVENESS EVALUATION OF PREHOSPITAL THROMBOLYSIS WITH TENECTEPLASE | Abstract similar documents |
| V. V. Omel'yanovskiy, E. V. Derkach, P. M. Khaylov, S. N. Tereshchenko | ||
| "... Aim. To evaluate clinical and cost effectiveness of different reperfusion strategies in myocardial ..." | ||
| Vol 7, No 3 (2011) | COSTS OF THE HEALTH CARE IN RUSSIA ASSOCIATED WITH SMOKING | Abstract similar documents |
| A. V. Kontsevaya, A. M. Kalinina | ||
| "... Aim. To analyze costs of health care in Russia associated with smoking in 2009. Material ..." | ||
| Vol 12, No 5 (2016) | Dabigatran Etexilate in the course of Electrical Cardioversion in Patients with Non-Valvular Atrial Fibrillation | Abstract similar documents |
| N. A. Novikova, A. N. Volovchenko | ||
| "... showed the efficacy and safety of rivaroxaban and apixaban in preparation and performance of electrical ..." | ||
| Vol 16, No 1 (2020) | Clinical Significance of Thrombin Blockade with Low Doses (2.5 mg) of Rivaroxaban in Ischemic Heart Disease Patients | Abstract similar documents |
| A. B. Sumarokov, L. I. Buryachkovskaya, Y. V. Docenko, M. S. Kurochkin, N. V. Lomakin | ||
| "... therapy turned out to be the most promising for clinical use, since studies with dabigatran and apixaban ..." | ||
| Vol 7, No 2 (2011) | SOCIO-ECONOMIC DAMAGE BY ACUTE CORONARY SYNDROME IN RUSSIAN FEDERATION | Abstract similar documents |
| A. V. Kontsevaya, A. M. Kalinina, I. E. Koltunov, R. G. Oganov | ||
| "... . Material and Methods. Direct costs and economic losses associated with ACS were estimated. The structure ..." | ||
| Vol 7, No 4 (2011) | VALUE OF THERAPEUTIC EQUIVALENCE IN SUBSTITUTION OF ORIGINAL DRUG WITH GENERIC BY EXAMPLE OF FOSINIPRIL | Abstract similar documents |
| N. P. Kutishenko, S. Yu. Martsevich, Zh. D. Kobalava, E. K. Shavarova | ||
| "... with arterial hypertension (HT) of 1-2 degrees, and to evaluate the cost effectiveness of original drug ..." | ||
| Vol 7, No 5 (2011) | ANALYSIS OF DIRECT COSTS ASSOCIATED WITH THE USE OF WARFARIN IN PATIENTS WITH ATRIAL FIBRILLATION | Abstract similar documents |
| Yu. B. Belousov, I. S. Yavelov, D. Yu. Belousov, E. V. Afanasieva | ||
| "... . The study was performed based on methodology for Cost of Illness evaluation. Expenses associated with INR ..." | ||
| Vol 8, No 1 (2012) | ANALYSIS OF COST STRUCTURE FOR PHARMACOTHERAPY OF PATIENTS WITH STABLE ANGINA (THE CASE OF CARDIOLOGY DEPARTMENT OF TVER REGIONAL CLINICAL HOSPITAL) | Abstract similar documents |
| M. A. Demidova, N. N. Kirilenko | ||
| "... Aim. To analyze the cost structure for pharmacotherapy of patients with stable angina (SA ..." | ||
| Vol 13, No 5 (2017) | WARFARIN AND ITS IMPORTANCE IN THE ERA OF NEW ORAL ANTICOAGULANTS. ISSUES OF MONITORING THE EFFECTIVENESS AND SAFETY OF TREATMENT | Abstract similar documents |
| S. Yu. Martsevich, Y. V. Lukina | ||
| "... of new OAC (NOAC) also appeared. In Russia, dabigatran, rivaroxaban and apixaban have been registered ..." | ||
| Vol 17, No 5 (2021) | Efficiency of the Left Atrial Appendage Thrombus Dissolution in Patients with Persistent Nonvalvular Atrial Fibrillation with Warfarin or Direct Oral Anticoagulants Therapy | Abstract PDF (Eng) similar documents |
| E. S. Mazur, V. V. Mazur, N. D. Bazhenov, Yu. A. Orlov | ||
| "... .6%) started or continued taking rivaroxaban 20 mg 1 time/day and 3 (4.4%) started or continued taking apixaban ..." | ||
| Vol 15, No 6 (2019) | Adherence to Treatment with New Oral Anticoagulants in Atrial Fibrillation Patients in Real Clinical Practice (Results of the ANTEY Study) | Abstract similar documents |
| S. Yu. Martsevich, Yu. V. Lukina, N. P. Kutishenko, S. N. Tolpygina, V. P. Voronina, N. A. Dmitrieva, O. V. Lerman, N. A. Komkova | ||
| "... recommended the use of rivaroxaban; 47 (23.4%) – the use of dabigatran and 43 (21.4%) – the use of apixaban ..." | ||
| Vol 9, No 1 (2013) | CLINICAL AND COST EFFECTIVENESS OF PREVENTIVE COUNSELING OF YOUNG PATIENTS WITH ARTERIAL HYPERTENSION IN PRIMARY HEALTH CARE | Abstract similar documents |
| M. I. Shupina, O. Ju. Korennova, E. N. Loginova | ||
| "... Aim. To study clinical and cost effectiveness of training of young patients with arterial ..." | ||
| Vol 8, No 1 (2012) | CHANGES IN THE COSTS OF HYPERTENSIVE CRISIS THERAPY DUE TO OPTIMIZATION OF DRUG SUPPLY IN THE PRE-ADMISSION CARE | Abstract similar documents |
| N. I. Gaponova, N. F. Plavunov, V. L. Baratashvili | ||
| "... Aim. To assess the changes in the costs of treatment of patients with hypertensive crisis (HC ..." | ||
| Vol 4, No 3 (2008) | INFLUENCE OF HEALTH SCHOOL TRAINING OF PATIENTS WITH ISCHEMIC HEART DISEASE ON PHARMACOTHERAPY PROFILE AND COST (АВС/VEN ANALYSIS) | Abstract similar documents |
| A. V. Kontsevaja, А. М. Kalinina, E. J. Spivak | ||
| "... Aim. To study influence of patient training in Health School on pharmacotherapy profile and cost ..." | ||
| Vol 6, No 4 (2010) | ECONOMIC EFFICIENCY OF THE IMPLEMENTATION OF THE PROGRAM OF CARDIOVASCULAR DISEASES MULTIFACTORIAL PREVENTION IN THE ORGANIZED COLLECTIVE OF TECHNICAL RESEARCH INSTITUTE | Abstract similar documents |
| A. V. Kontsevaya, A. M. Kalinina, S. V. Belonosova, J. M. Pozdnjakov, M. B. Khudyakov | ||
| "... consultation. Costs associated with cardiovascular diseases and risk factors (medical care consumption ..." | ||
| Vol 9, No 4 (2013) | COMPARISON OF DIRECT COSTS OF DABIGATRAN AND WARFARIN THERAPY IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION DURING PREPARATION FOR ELECTIVE CARDIOVERSION IN THE REAL CLINICAL PRACTICE | Abstract similar documents |
| L. E. Kuvshinova, N. V. Furman, P. V. Dolotovskaya, Ya. P. Dovgalevsky | ||
| "... Aim. To compare direct medical costs of dabigatran and warfarin therapy in patients with non ..." | ||
| Vol 8, No 3 (2012) | PHARMACOECONOMIC ASPECTS OF NICOTINE ADDICTION TREATMENT IN PATIENTS WITH ANGINA REQUIRING CARDIAC SURGERY | Abstract similar documents |
| A. V. Rudakova, M. S. Berezhnova | ||
| "... the rejection of it are an important part of the treatment. Aim. To analyze the cost effectiveness ..." | ||
| Vol 11, No 4 (2015) | EVALUATION OF COST-EFFECTIVENESS OF PLATELET REACTIVITY ANALYSIS USING THE VERIFYNOW P2Y12 ASSAY IN PATIENTS AFTER ACUTE CORONARY SYNDROME | Abstract similar documents |
| A. V. Rudakova, N. V. Lomakin | ||
| "... . To assess the cost-effectiveness of VerifyNow P2Y12 platelet reactivity testing in patients after ACS ..." | ||
| Vol 15, No 5 (2019) | Costs and Evaluation of Vital and Essential Medicines for Internal Diseases Treatment, Purchased by Medical Organizations with the Funding from the System of Obligatory Medical Insurance in 2017 | Abstract similar documents |
| O. M. Drapkina, A. V. Kontsevaya, M. V. Sura, R. N. Shepel, L. M. Zhamalov | ||
| "... Aim. To assess the cost and importance of the vital and essential medicines for the treatment ..." | ||
| Vol 8, No 1 (2012) | PHARMACOECONOMIC EVALUATION OF DABIGATRAN VS WARFARIN IN CARDIOVASCULAR EVENTS PREVENTION IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION | Abstract similar documents |
| Yu. B. Belousov, V. Yu. Mareev, I. S. Yavelov, D. Yu. Belousov | ||
| "... the cost-effectiveness of dabigatran etexilate versus warfarin prescribed in “real-world” settings from ..." | ||
| Vol 14, No 2 (2018) | PHARMACOECONOMIC ANALYSIS OF CHRONIC HEART FAILURE DRUG THERAPY IN PATIENTS WITH COMORBID CONDITIONS | Abstract similar documents |
| S. K. Zyryanov, A. E. Cheberda, D. Yu. Belousov | ||
| "... of treatment and clinical practice results was built. Cost-effectiveness analysis was done by comparing two ..." | ||
| Vol 16, No 5 (2020) | Pharmacoeconomic Analysis of Therapy with Generic Statin Drugs in Patients with High and Very High Cardiovascular Risk (According to the Study PRIORITY) | Abstract similar documents |
| S. Yu. Martsevich, Yu. V. Lukina, N. P. Kutishenko | ||
| "... the results of the lipid profile. To perform a pharmacoeconomic analysis and evaluate the “cost/effectiveness ..." | ||
| Vol 17, No 1 (2021) | Optimization of the Statin Therapy Algorithm in Outpatient Practice: Adherence and Economic Benefits | Abstract similar documents |
| S. A. Davitashvili, D. V. Nebieridze, N. M. Akhmedzhanov, A. S. Lishuta, A. S. Safaryan | ||
| "... adherence, effects on surrogate and hard endpoints, and cost-effectiveness of the two statin regimens were ..." | ||
| Vol 10, No 2 (2014) | PRIMARY PREVENTION OF MYOCARDIAL INFARCTION IN MIDDLE-AGED MALES (15-YEAR FOLLOW-UP): CLINICAL AND ECONOMIC ASPECTS OF THE PROBLEM | Abstract PDF (Eng) similar documents |
| A. M. Kalinina, A. V. Kontsevaya | ||
| "... . Cost-effectiveness of primary prevention, including the one of MI, has been conclusively showed ..." | ||
| Vol 20, No 5 (2024) | Effectiveness and safety of direct oral anticoagulants in patients with atrial fibrillation and chronic kidney disease: a systematic review and meta-analysis of clinical trials | Abstract similar documents |
| E. M. Mezhonov, Z. M. Safiullina, Y. A. Vyalkina, S. V. Shalaev | ||
| "... " or "dabigatran" or "apixaban" or "rivaroxaban" and "vitamin K antagonist" or "warfarin" and "outcomes". ROBINS-I ..." | ||
| Vol 21, No 1 (2025) | Practical aspects of perioperative management in patients with non-valvular atrial fibrillation receiving direct oral anticoagulants | Abstract similar documents |
| E. N. Markova, T. Yu. Vedenikin, A. A. Kuzub, N. V. Kuchieva, A. R. Navasardyan, O. N. Dzhioeva | ||
| "... and hemorrhagic complications, and the need for venous thromboembolism (VTE) prophylaxis. Special attention ..." | ||
| Vol 12, No 1 (2016) | Pharmacoeconomic analysis of heart rate slowing drugs in patients with ischemic heart disease | Abstract similar documents |
| E. I. Tarlovskaya, T. I. Chudinovskikh | ||
| "... Aim. To compare the efficacy and cost/effectiveness ratio of the original and generic bisoprolol ..." | ||
| Vol 9, No 1 (2013) | PHARMACOEPIDEMIOLOGICAL AND PHARMACOECONOMIC STUDIES OF ANTIHYPERTENSIVE TREATMENT IN RUSSIA. Analytical Review | Abstract similar documents |
| T. S. Romanenko, A. V. Kontsevaya, S. V. Fitilev | ||
| "... therapy, conducted during the last decades inRussia. Despite the increased interest to the issue of cost ..." | ||
| Vol 5, No 3 (2009) | CLINICAL AND ECONOMICAL RATIONALES OF CARDIOVASCULAR RISK EVALUATION AT WORKPLACE | Abstract similar documents |
| A. V. Kontsevaya, A. M. Kalinina, Yu. M. Pozdnyakov, S. V. Belonosova, M. B. Khudyakov | ||
| "... (with estimation of the total costs, costs for one studied person and costs for revealing of one person needed ..." | ||
| Vol 3, No 4 (2007) | THE ALGORITHMIC MODEL OF LABORATORY DIAGNOSTICS OPTIMIZATION | Abstract similar documents |
| G. I. Nazarenko, O. V. Andropova | ||
| "... of algorithmic approach is able to optimize diagnostics and its costs. Various algorithmic models, their features ..." | ||
| Vol 7, No 1 (2011) | THE CHOICE OF THE DRUG AMLODIPINE FOR THE HYPERTENSION TREATMENT FROM THE STANDPOINT OF ECONOMIC FEASIBILITY | Abstract similar documents |
| S. Yu. Martsevich, N. A. Dmitrieva, A. D. Deev, Yu. V. Lukina, L. A. Sokolova, V. V. Yakusevich | ||
| "... Aim. Тo compare the cost-effectiveness of antihypertensive therapy based on a generic and original ..." | ||
| Vol 8, No 2 (2012) | PRELIMINARY RESULTS OF COMPARATIVE PHARMACOECONOMIC PROSPECTIVE STUDY OF DIFFERENT THERAPIES OF ARTERIAL HYPERTENSION | Abstract similar documents |
| E. I. Tarlovskaya, N. S. Maksimchuk, S. V. Malchikova, M. V. Avksentieva | ||
| "... (LVMI) were considered. Cost-effectiveness method of analysis was used. Results. In V/A group 75 ..." | ||
| 1 - 100 of 145 Items | 1 2 > >> | |
Search tips:
- Search terms are case-insensitive
- Common words are ignored
- By default articles containing any term in the query are returned (i.e., OR is implied)
- Make sure that a word exists in an article by prefixing it with +; e.g., +journal +access scholarly academic
- Combine multiple words with AND to find articles containing all terms; e.g., education AND research
- Exclude a word by prefixing it with - or NOT; e.g., online -politics or online NOT politics
- Search for an exact phrase by putting it in quotes; e.g., "open access publishing". Hint: Quoting Chinese or Japanese words will help you to find exact word matches in mixed-language fields, e.g. "中国".
- Use parentheses to create more complex queries; e.g., archive ((journal AND conference) NOT theses)
